Table 4.

Comparison of incidences of graft-versus-host disease in subgroups of patients treated by bulk dose regimen

<1.5 × 108 (n = 11)≥1.5 × 108 (n = 11)
Relapse stage 
 Cytogenetic  2  5  
 Hematologic–CP  8  
 Hematologic–AP  1  1  
Complete remission  6 (54%) 9 (81%)  
GVHD:  
 Acute  
  Grades 0-1  6  
  Grade 2  1  3  
  Grades 3-4  4  
 Chronic  
  None/limited  6  
  Extensive 
<1.5 × 108 (n = 11)≥1.5 × 108 (n = 11)
Relapse stage 
 Cytogenetic  2  5  
 Hematologic–CP  8  
 Hematologic–AP  1  1  
Complete remission  6 (54%) 9 (81%)  
GVHD:  
 Acute  
  Grades 0-1  6  
  Grade 2  1  3  
  Grades 3-4  4  
 Chronic  
  None/limited  6  
  Extensive 

GVHD, graft-versus-host disease.

Lymphocyte doses ranged from <1.5 × 108/kg to >1.5 × 108/kg.

or Create an Account

Close Modal
Close Modal